What changed
What changedMcKesson Corporation reported preliminary results for the quarter ended September 30, 2026. Consolidated revenue grew 8% to $111 billion. Earnings per diluted share (EPS) for the period were $10.44, up $1.52 from the year-ago quarter.

Company history
October 2026
MCKESSON CORP: 11 recorded developments from 4 official sources in 2026-10.
- 2026-10-06: At the closing of the transaction, CD&R will hold a majority ownership interest, and McKesson will hold a minority ownership interest. Source
- 2026-10-06: Option Care Health will remain a separate company led by its own management team. Source
- 2026-10-06: This investment represents an important opportunity that aligns with McKesson’s long-term strategy to expand access and affordability to innovative therapies across the care continuum. Source
- 2026-10-06: As a strategic investor, we look forward to bringing McKesson’s experience and expertise in specialty pharmaceuticals to support Option Care Health’s strategy of broadening access to complex therapies and enabling care delivery in lower-cost settings, while creating long-term value for s Source
- 2026-10-06: Option Care Health will continue to operate as usual, with the same commitment to its patients, providers, employees, and partners. Source
- 2026-10-06: Under the definitive agreement, CD&R will hold a majority interest of approximately 51% in Option Care Health and McKesson will invest approximately $1.4 billion for a minority interest of approximately 49%. Source
- 2026-10-06: The transaction value represents a premium of approximately 37% to Option Care Health’s closing share price on October 5, 2026, the last full trading day of Option Care Health’s common stock prior to the transaction announcement. Source
- 2026-10-06: Upon completion of the transaction, Option Care Health’s common stock will no longer be publicly listed on the Nasdaq Stock Exchange, and Option Care Health will become a privately held company. Source
- 2026-10-15: Units to be sold: 801; aggregate market value: 797128.94 USD; units outstanding: 116590363 Source
- 2026-10-19: Summary: S (open market or private sale): 1 transaction(s) on 2026-10-15, 800.491 disposed, total value 797,128.94 USD at a weighted average price of 995.8 USD; owned after the last one: 5,423.496 Source
- 2026-10-30: The New York Stock Exchange filed a notification of removal from listing for MCKESSON CORP's 1.625% Notes due 2026. Source
August 2026
MCKESSON CORP: 3 recorded developments from 1 official source in 2026-08.
- 2026-08-01: McKesson Corporation received a federal contract new award of $1,159,388,670.44 from the Department of Veterans Affairs for Express Report: Pharmaceutical Prime Vendor (PPV) FY2026 Aug. Source
- 2026-08-01: The award ID for the federal contract is 36C24026K1011. Source
- The action date for the federal contract is 2026-08-01. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Expectations and reality
Open
Fiscal 2027 adjusted earnings per diluted share guidance indicates 17% to 19% growth compared to the prior year.
Said November 4, 2026 · Period named: Fiscal 2027 · Source · Our article
Not yet checked against later reports.
The Prescription Technology Solutions segment initiative is anticipated to be substantially complete by the end of fiscal 2029.
Said November 4, 2026 · Period named: fiscal 2029 · Source · Our article
Not yet checked against later reports.
McKesson raised its fiscal 2027 Adjusted Earnings per Diluted Share guidance to $45.60 to $46.40 from the previous range of $44.20 to $45.00.
Said November 4, 2026 · Period named: fiscal 2027 · Source · Our article
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Changes in risk factors
The 10-Q filed November 4, 2026 compared with the 10-Q filed August 5, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC
Added (37)
- Additional information regarding the factors affecting our results is included in "Results Of Operations" within the consolidated discussion of Revenues.
- Revenues | $ | 110,957 | | | $ | 103,150 | | | 8 | | % | | $ | 216,337 | | | $ | 200,977 | | | 8 | | %
- Gross profit | 3,956 | | | 3,542 | | | 12 | | | | 7,641 | | | 6,821 | | | 12
Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.
Governance events
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|
| October 30, 2026 | Removal of a security from listing (Form 25) | 25-NSE |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 10,089,926 | $8,614,879,713 | -6.5% | Q3 2026 |
| State Street | 5,545,855 | $4,740,385,578 | -3.2% | Q3 2026 |
| Geode Capital Management | 2,976,448 | $2,532,053,133 | +5.5% | Q3 2026 |
| Fidelity (FMR) | 2,857,219 | $2,439,521,544 | +34.1% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 1,529,056 | $1,155,354,714 | — | Q2 2026 |
| D. E. Shaw & Co. | 503,088 | $429,541,565 | +4.0% | Q3 2026 |
| Citadel Advisors | 217,856 | $186,007,631 | -52.7% | Q3 2026 |
| Renaissance Technologies | 195,166 | $166,634,682 | -46.0% | Q3 2026 |
| Millennium Management | 120,273 | $102,690,290 | +18.9% | Q3 2026 |
| Bridgewater Associates | 72,711 | $62,081,379 | +3.3% | Q3 2026 |
| Wellington Management | 25,413 | $21,697,874 | -47.3% | Q3 2026 |
| Two Sigma Investments | 922 | $787,213 | -85.7% | Q3 2026 |
| T. Rowe Price | 585,208 | $499,657 | -7.1% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.